Literature DB >> 7417959

Malignant mesothelioma in North America.

A D McDonald, J C McDonald.   

Abstract

Ascertainment, through 7,400 pathologists, of all fatal malignant mesothelial tumors in Canada (1960-75) and the U.S.A. (1972) gave a total of 668 cases (272 in 1972). In Canada, the annual number of male cases rose from about 17 in 1966 to 25 in 1972 but the number of female cases remained fairly steady at a much lower level. The annual incidence in North America in 1972 was estimated at 2.8 per million males and 0.7 per million females aged 15 years and over. Occupational histories were obtained "blind" for 480 of the 557 cases through 1972, and their matched controls; relative risks were as follows: insulation work, 46.0 asbestos production and manufacture, 6.1, heating trades (other than insulation) 4.4. For nearly half the male cases and for about 5% of female cases, the tumor could be attributed to occupational exposure to asbestos, of which a fifth were in shipyards. No indication was found of other possible causes (including man-made mineral fibers, tobacco smoking, or residence near zeolite deposits). Four subjects were men who had been employed in Quebec chrysotile mines and 3 were children of employees, but no other subject had lived in the mining area. The findings remain consistent with a much greater mesothelioma-producing potential for crocidolite and amosite than for chrysotile; however, further studies of factory workers exposed to chrysotile only are needed to confirm this. Mineral fiber analysis of lung tissue from patients and controls is in progress.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7417959     DOI: 10.1002/1097-0142(19801001)46:7<1650::aid-cncr2820460726>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

Review 1.  Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis.

Authors:  V Bourdès; P Boffetta; P Pisani
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

2.  Surveillance of nasal and bladder cancer to locate sources of exposure to occupational carcinogens.

Authors:  K Teschke; M S Morgan; H Checkoway; G Franklin; J J Spinelli; G van Belle; N S Weiss
Journal:  Occup Environ Med       Date:  1997-06       Impact factor: 4.402

Review 3.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

4.  Routes of asbestos exposure and the development of mesothelioma in an English region.

Authors:  D Howel; L Arblaster; L Swinburne; M Schweiger; E Renvoize; P Hatton
Journal:  Occup Environ Med       Date:  1997-06       Impact factor: 4.402

5.  Combined effect of asbestos and smoking on mortality from lung cancer and mesothelioma in factory workers.

Authors:  G Berry; M L Newhouse; P Antonis
Journal:  Br J Ind Med       Date:  1985-01

6.  Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells.

Authors:  N-Y Kim; M-C Kim; Y Kim
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

7.  [Pleural mesothelioma--problems in diagnosis and clinical course in 25 patients].

Authors:  F Liewald; L Sunder-Plassmann; H Dienemann; J Mezger
Journal:  Langenbecks Arch Chir       Date:  1989

8.  Malignant mesothelioma in women.

Authors:  A Dawson; A R Gibbs; F D Pooley; D M Griffiths; J Hoy
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

9.  Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology.

Authors:  W E Wright; R P Sherwin; E A Dickson; L Bernstein; J B Fromm; B E Henderson
Journal:  Br J Ind Med       Date:  1984-02

Review 10.  The health impact of nonoccupational exposure to asbestos: what do we know?

Authors:  Marcel Goldberg; Danièle Luce
Journal:  Eur J Cancer Prev       Date:  2009-11       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.